netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Study Tests Stem Cell-based Therapy for Advanced Dry AMD

RPB-supported researchers and physicians at the University of Southern California (USC) Roski Eye Institute have collaborated with other California institutions to show that a stem cell-based retinal implant is feasible for use in people with advanced dry age-related macular degeneration (AMD), according to a press release by the Institute. The results of the study were published in the scientific journal Science Translational Medicine.

A photo of the implant used in the study.

 

Photo credit: Britney O Pennington, PhD

The treatment, which consists of a layer of human embryonic stem cell-derived retinal pigment epithelium cells on an ultrathin supportive structure, was implanted in the retina of four patients by a USC Roski Eye Institute surgeon. The patients were followed for up to one year to assess its safety and the treatment was well-tolerated. There was also evidence that the implant integrated with the patients' retinal tissue, which is essential for the treatment to be able to improve visual function.

Amir Kashani, MD, PhD, lead author and surgeon for the study, in his lab.

 

Photo credit: Richard Carrasco, Keck Medicine of USC

As part of the study, the research team also performed a preliminary assessment of the therapy's efficacy. One patient had improvement in visual acuity, which was measured by how many letters they could read on an eye chart, and two patients had gains in visual function, which was measured by how well they could use the area of the retina treated by the implant.

"Our study shows that this unique stem cell-based retinal implant thus far is well-tolerated, and preliminary results suggest it may help people with advanced dry age-related macular degeneration," says coauthor and lead inventor of the implant Mark S. Humayun, MD, PhD, director of the USC Institute for Biomedical Therapeutics, co-director of the USC Roski Eye Institute, affiliate principal investigator with the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC and university professor of ophthalmology at the Keck School.

Read the full ARticle from USC here

Related News: Feature Story, Macular Degeneration, Stem Cell Therapy, Top Story

Dr. Semenza and colleague work in his lab

Research to Prevent Blindness Grantee Dr. Gregg Semenza Wins Nobel Prize in Medicine

Dr. Semenza is being recognized for his discoveries related to how cells respond to low oxygen levels, which have implications for the treatment of cancer, eye diseases and more.

Read More

 
RPB logo

RPB and Partners Award $1.2 Million In Grants for Novel AMD Research

Four new grantees received the Catalyst Awards for Innovative Research Approaches for AMD.

Read More

 
CDA 30th Anniversary book

The Career Development Award Turns 30: Celebrating a Generation of Support for Early-Career Scientists

CDA founded 30 years ago as one of the few private sources of funding aimed specifically at early-career vision researchers.

Read More

 
Retinal image of person with Alzheimer's disease

Could An Eye Exam Reveal Alzheimer’s Disease?

Study from RPB-supported researchers at Duke University suggests loss of blood vessels in retina reflect changes in brain health.

Read More

 
Gregory Schwartz in the lab

New Findings on Blood Vessel Regulation

A study from an RPB-supported researcher at Northwestern University School of Medicine could speed up the diagnosis of retinal diseases.

Read More

 
NEI Audacious Goals image and text

RPB-SUPPORTED RESEARCHERS INTEGRAL TO NEI’S AUDACIOUS GOALS INITIATIVE

Vision scientists who have received RPB funding will help lead all five research teams, which will seek to accelerate development of regenerative treatments for blindness.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.